FDA continues to issue warning letters to firms that distribute unapproved new drugs to prevent or treat COVID-19 infections. In addition, this week FDA posted three warning letters to drug firms, one to a device firm, and one to a compounding pharmacy. We cover these five below.

Drug Warning and Untitled Letters

Kumar Organic Products Limited

Kumar Organic Products Limited (Gujarat, India) received a warning letter on April 23, 2020, based on the outcome of an inspection ending November 14, 2019. The firm produces an API that is by definition an in-process material for a finished drug product and therefore subject to 21 CFR 211.  The firm manufactures an OTC topical product(s). FDA recommends the firm hire a qualified GMP consultant to help them come into GMP compliance.

Deficiencies include but are not limited to:

  • The firm’s water system is not appropriately designed, maintained, or monitored to ensure it produces water of appropriate quality for its intended use. (It’s interesting how “water” is redacted but it’s pretty straightforward to figure it out.  Makes no sense to me, particularly when product names are often not redacted). Several deficiencies were identified that could lead to the formation of biofilms in the system. Sampling intervals were inadequate and testing of the final product cannot substitute for microbiological testing of the water. That’s an approach I’ve not seen before! The firm actually stated they “have not designed [the] system to control bioburden.”

  • The firm failed to test incoming components for identity, nor had they validated and established the reliability of the suppliers’ data. The firm also uses a technical grade of what I assume is glycerine because FDA finds fault with their failure to test for diethylene glycol prior to release for use in the manufacture of products. While the firm did commit to perform impurity testing for diethylene glycol and related substances and to revise the vendor qualification to include qualification of raw materials to verify the data on the COA, FDA did not accept their response. FDA deemed the response inadequate because they did not commit to testing all retain samples to ensure they were of adequate quality. 

International Trading Pharm Lab Inc

International Trading Pharm Lab Inc (Paterson, NJ) received a warning letter on April 24, 2020, based on the outcome of an inspection ending October 29, 2019. The company is a contract testing laboratory. FDA notes that because they don’t conform to GMPs the APIs that they test are deemed adulterated. FDA reminds them they are considered an extension of the manufacturers/sponsors’ operations. They also recommend that the firm hire a qualified consultant to help them come into GMP compliance. FDA also notes, Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you test,” and follows up with a detailed set of requirements for data integrity remediation.  

Deficiencies include but are not limited to:

  • The Quality Unit does not adequately oversee laboratory operations. Several chromatography results, including injections, were not captured in laboratory notebooks, not documented in the OOS investigations which they were intended to support, and not provided for QA consideration during lot release. The firm’s response to the observation was inadequate because the firm did not commit to a review of all chromatography data to determine the extent of this practice. 

  • The firm’s OOS investigations were closed without adequate scientific justification. During the inspection, the firm told the investigator “…without the permission and authorization of the client, your firm is limited to what can be tested on the sample in case of failure.The firm’s response to the observation was not adequate and, further, FDA pointed out this was not correct and that the contract testing laboratory must follow GMPs regardless of the outcome of discussions with clients. 

  • The firm conducted assays and identity testing on multiple API samples without first performing a verification that the method performs adequately under actual conditions of use. The firm tried to explain that system suitability served that function, but the FDA did not accept that response. 

  • The firm does not have adequate controls to ensure the integrity of electronic test data from HPLCs and GS. Standalone instruments gave analysts the ability to delete raw data and alter the date and time stamps, audit trails were not enabled so it is impossible to determine if any data were manipulated. The firm’s response was inadequate because it did not address the lack of audit trails. And for anyone who still thinks that paper is the original data FDA notes, “You also included a corrective action to print all chromatograms for each analysis. Electronic records are dynamic, and a printout or a static record does not preserve the dynamic record format that is part of the complete original record.”

In addition, FDA provides their usual boilerplate language for data integrity remediation.

Blaine Labs Inc

Blaine Labs Inc (Santa Fe Springs, CA) received a warning letter on May 5, 2020, based on the outcome of an inspection ending May 5, 2020. The firm manufactures a psoriasis treatment that is an unapproved new drug. FDA identifies unapproved new drug charges within the warning letter and recommends the firm hire a qualified consultant(s) to assist them in coming into GMP compliance.

The deficiencies include but are not limited to:

  • Failure to adequately investigate OOS results, lack of adequate investigation of OOS results for viscosity was cited in the November 2015 inspection. Quality released material without adequately investigated OOS results, including that for a raw material that failed a microbial specification. FDA deemed the firm’s response to be inadequate because it did not ensure that failures were adequately remediated. They also did not commit to a retrospective review of all drug products to ensure that root causes for deviations are adequately established and CAPAs implemented to prevent them from recurring.

  • The firm did not validate the manufacturing process for products nor did they qualify equipment, extensive hold times (that apparently ran into months), or cleaning validation. These are repeat deficiencies from a November 2015 inspection. The firm’s response was inadequate because they did not provide adequate detail on how they would validate processes and cleaning. Further, FDA refers them to the FDA Guidance on Process Validation

  • Water from an unvalidated system that was not adequately monitored was used in cleaning and in the manufacture of drug products. FDA determined that the firm’s response was inadequate because they did not demonstrate they implemented a proper system design that will ensure a state of control. 

  • The Quality Unit failed to exercise its authority and responsibilities as demonstrated by:

    • The firm had multiple versions of a bulk test report that were not approved by Quality.

    • The QC laboratory used loose paper to document original test data which were subsequently transcribed into formal test reports. The loose paper was not retained or reviewed, laboratory notebooks or worksheets were not used. In addition, laboratory staff signed off on their own test results without second person verification.

    • No written approved procedures were available that described process validation, equipment qualification, OOS investigations, stability program, or change controls for the manufacturing processes. 

Device Warning and Untitled Letters

Lymol Medical Corporation

Lymol Medical Corporation (Woburn, MA) received a warning letter on April 7, 2020, based on the outcome of an inspection ending February 12, 2020. The speed with which FDA took enforcement action highlights the potential danger of the firm’s products to the public. They manufacture reusable bronchoscope systems and silicone stents and seem to have failed to understand the most basic of QSR requirements. 

Deficiencies include but are not limited to:

  • The firm has not validated the cleaning instructions, sterilization instructions, or storage conditions provided to hospitals for the bronchoscope, a reusable device.  

  • The firm has not established adequate documentation for the identification, documentation, and validation, and approval of design changes before their implementation.  

  • The firm does not have and maintains documentation and acceptance activities of component parts.

  • The firm has failed to evaluate complaints about potential reporting under MDR requirements. Further, the complaint process is not adequate because investigations are not performed. FDA provides detailed examples. 

  • Failure to establish and maintain purchasing documents that describe requirements that must be met for purchased components.  

  • Failure to establish and maintain Device History reports for each batch. 

Letters to Compounding Pharmacies and Outsourcing Facilities

IntegraDose Compounding Services LLC

IntegraDose Compounding Services LLC (Minneapolis, MN) received a warning letter on May 6, 2020. FDA states that the firm failed to manufacture sterile drugs under appropriate conditions and cite both the FD&C Act and 21CFR211 in the identified deficiencies. Further, they indicate that the drugs are misbranded because labeling did not provide adequate instructions for use. And finally, the facility failed to report adverse events as required by law.

BIMO, GCP and GLP Warning and Untitled Letters 

No letters were issued this week. 

Download the Special Report

Quality Week report sidebar

What You Will Learn from This Report:

How a major pharmaceutical company designed a program to train future leaders in quality

An industry-led initiative to advance the state of quality in the pharma industry

A pharma GMP leader’s tips for supporting quality culture within an organization

An update on FDA’s Quality Maturity Model

Redica Systems Enforcement Analytics

Compare two companies of your choice.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Evaluate Your CDMOs

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Compare the inspection history of your CDMO sites.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Compare the enforcement history of your CDMOs.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Monitor compliance at your Clinical Investigator sites.

Enter your email address and someone will contact you shortly to get you started.

Redica Systems Enforcement Analytics

Prepare for inspections of Clinical Investigator sites.

Enter your email address and someone will contact you shortly to provide more Clinical Investigator data about your sites.

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore enforcement trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore observations and trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to run your custom report.

Redica Systems Enforcement Analytics

Get help choosing the right CRO.

Enter your email address and someone will contact you shortly to customize your insights.

Download the Special Report

Download your copy of THE FDA INSPECTION LANDSCAPE IN MID-2020 AND A LOOK AT VIRTUAL INSPECTION

In this summary we identify:

  • Trend analysis of FDA inspections through mid-2020
  • Strategies for preparing and hosting virtual inspections
  • New technologies to support remote inspections
Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need to prepare for your next inspection.

Download the Special Report

CDMO Comparison opt-in

In this summary we identify:

FY2018-FY2020 GMP data for Lonza & Catalent

Top GMP primary citations

Top FDA 483 observations

Panel Discussion – Remote Audits

Panel Discussion opt in image

Featuring Panelists:
—Barbara W. Unger, Unger Consulting, Inc.
—Jerry Chapman, Redica Systems
—Stephanie Gaulding, Pharmatech Associates

Who Will Benefit?
This session will be valuable to GMP quality, regulatory, compliance, and management personnel in FDA-regulated industries who want to have a conversation on remote audits and get to know what is going on in the industry.

Turning Failure into Success

Presented on Tuesday, April 27, 2021 by Steve Greer, Executive Coach, Genesis Assist, and former Quality Leader, Procter and Gamble

What you will learn:

  • How to use the Leadership SOS Model to transform quality culture
  • How to strengthen quality systems to eliminate human error
  • How to generate ideas on how to set your organization up for success for shareholders, FDA, and staff
Redica Systems Enforcement Analytics

Get Full Access to Redica Enforcement Analytics

Enter your email address and someone will contact you shortly to answer all of your questions and get you started.

Quality Management Systems for Small Pharma and Biotech Firms

Webinar: QMS for Small Pharma and Biotech Firms

Presented by Fenton Fong, Founder, Managing Director, & Principal at xCellarate

Get instant access to the webinar video and slides.

What you will learn:

  • Common challenges small pharma firms face when developing a QMS
    Recent enforcement trends involving the Quality Unit
    Impact of the COVID-19 pandemic

Download the Special Report

APAC ad

In this summary we identify:

GMP data from FY2017 to FY2020 for the Asia-Pacific region

Top 3 GMP primary and secondary citations

Top 3 483 observations

Download the Special Report

An Analysis Of MHRA’s Latest Annual GMP Inspection Deficiencies Report

In this summary we identify:

  • Data from 2019 UK MHRA Inspections
  • Trends from 2015, 2016, 2018, and 2019 inspections
  • Conclusions drawn from an analysis of drug inspection data

Experience the Power of Redica Systems

Redica_Vert_Periwinkle_RGB_Large

SEARCH Find the inspection records you want by inspector’s name, company name, site, city, country, etc.

WARNING LETTERS Easily search the largest database of FDA Warning Letters by date, company, FDA office, or subject

SITES Quickly assess inspection records including dates and inspectors across all of your sites

INSPECTIONS Complete list of FDA inspections by date, company, category, and country

Get Complete Access to the Redica Systems Platform

Please submit your email address and one of our team members will contact you shortly to answer all of your questions and get you started with the new Enforcement Analytics platform.

Experience the Power of Redica Systems

Complete the form and one of our experts will reach out to you to schedule a demo and answer questions about our subscription options.

INDEX INFORMATION  Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

STRENGTHEN DATASETS Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

ANALYZE & INTERPRET PATTERNS Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Impact of the Global Pandemic on Recent Data Integrity and Regulatory Non-compliance Trends

Webinar: Impact of the Global Pandemic on Recent Data Integrity and Regulatory Non-compliance Trends

Presented by Paul Smith, Agilent Technologies on Aug. 26, 2020

What you will learn:

  • Examples of essential laboratory actions to remain compliant during the pandemic
  • Recent data integrity non-compliance findings and trends
  • Essential strategies to find, understand, and leverage regulatory non-compliance data

Get the scoop on recent data integrity 483 observations!

  • FY 2020 Data Integrity 483 Observations
  • Data Integrity Observations for Human Drugs
  • Observations Falling Under GMP
  •  

Past, Present, and Future of Quality Culture

Presented by Regulatory Compliance Associates Distinguished Fellow Susan Schniepp

What you will learn:

  • How the 2014 FDA quality metrics initiative led to greater focus on quality culture
  • New quality culture tools and standards under development by PDA and other organizations
  • Best practices for quality culture, including case studies with lessons learned

Changing Medical Device Regulations

Presented by Redica Systems 

What you will learn:

  • The latest developments regarding the EU MDR
  • Quality Systems requirements for medical devices
  • Regulatory updates affecting medical devices

Download the Special Report

Combination Product Report

What You Will Learn from This Report:

The latest U.S. and European regulatory developments

The impact of smart combination products

How the EU MDR impacts drug-device combination products

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

In-depth analysis of the findings

Lessons learned

How companies can avoid similar shortcomings.

Experience the Power of Redica Systems

Redica Systems Expert Jerry Chapman to Present at SQA Annual Meeting

Index Information Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

Strengthen Datasets Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

Analyze & Interpret Patterns Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Download the 510(k) Sample

What You Will Learn from This Sample:

See how a 510(k) submission is structured

Find out what information to include

Review correspondence between sponsor and FDA

Redica Systems Enforcement Analytics

Unlimited Access to Reports and Data

Enter your email address and someone will contact you shortly.

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

The first countrywide import alert issued by FDA

An inadequate deviation investigation

An inadequate product specifications and a product recall

Process validation issues at a CMO

A different perspective on process validation and the culpability of the quality unit

 

A.I. for Quality and Compliance Teams

August 3 webinar

Presented by Redica Systems Senior GMP Quality Expert Jerry Chapman

What you will learn:

  • A basic understanding of data sources, machine learning, NLP, and A.I. tools
  • Building and applying Expert Models
  • Two case studies, one on sterile manufacturing/503B and one on data integrity

Human Factors – Compliance and Applications

June webinar

Presented by Alison Sathe, Founder, Regulatory Mark & Valerie Fenster, Director of Insights and  Human Factors, Kaleidoscope Innovation 

What you will learn:

  • Human factors strategies from simple drug products to complex surgical devices
  • Primary and secondary labeling development and evaluation for usability
  • Human factors activities from product development to post-market
  • International strategies: expectations for human factors in regulatory submissions in international markets

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Sign up for your FREE account today and get instant access to Enforcement Analytics.

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Let us know who you are and we’ll be in touch to answer all of your questions and get you started.

Redica Systems Enforcement Analytics

Keep up with the latest Regulatory Developments on Clinical Trials

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save your team valuable time when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save time and Resources when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Get immediate access to the news that matters to your sites.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

See how we can help you eliminate yet another spreadsheet.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Stay ahead of changing regulations.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO monitoring strategy.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO management strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Discover the power of the most comprehensive database of 483s in existence.

Our database of over 20,000 483s is retyped and tagged, making it easy to create an Observation Report in seconds.

Eliminate days of work and get your FREE personalized 483 Observation Report.